Form 4: CYTK CEO Sells Shares Under 10b5-1 Plan

Cytokinetics CEO Robert I. Blum sold 5,000 shares of common stock for $62.86 per share on October 30, 2025, under a pre-arranged trading plan.

Summary

• Robert I. Blum, President & CEO and Director of Cytokinetics Inc. (CYTK), reported a sale of common stock.
• The transaction involved the disposition of 5,000 shares of common stock.
• The shares were sold at a price of $62.86 per share.
• The transaction occurred on October 30, 2025.
• The sale was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• Following the reported transaction, Robert I. Blum directly beneficially owns 358,108 shares of common stock.
• Additionally, 2,083 shares are indirectly beneficially owned by The Bridget Blum 2003 Irrevocable Trust, and another 2,083 shares are indirectly beneficially owned by The Brittany Blum 2003 Irrevocable Trust.

Sentiment

Score: 5

Explanation: The insider sale, while reducing the CEO's direct holdings, was conducted under a Rule 10b5-1 plan, indicating it was pre-scheduled and not necessarily a reaction to new information. This mitigates the potential negative sentiment often associated with insider selling, making the overall sentiment neutral to slightly negative.

Negatives

• An insider sale, even under a pre-arranged plan, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake.

Future Outlook

NA

Industry Context

This filing is a standard insider transaction report and does not provide information directly related to broader industry trends or competitive landscape. It reflects an individual executive's equity management.

Related Party Transactions

• Indirect beneficial ownership of shares by The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust, which are related parties to Robert I. Blum.

Stakeholder Impact

• Shareholders may interpret the insider sale differently; some may view it as a routine diversification or liquidity event due to the 10b5-1 plan, while others might perceive it as a slight reduction in management's conviction.

Key Dates

Recommendation

The sale by CEO Robert I. Blum was conducted under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not necessarily a reflection of new sentiment regarding the company's immediate prospects. While insider sales can sometimes be viewed negatively, the pre-planned nature mitigates this concern. Without further context on the company's fundamentals or other market factors, this single transaction alone does not warrant a change from a 'hold' position.

Keywords

CYTK, Cytokinetics, Insider Trading, Form 4, Stock Sale, Robert I Blum, CEO, Director, 10b5-1 Plan